Hikma announces CEO change and Board appointment

On 15 December 2025, Hikma Pharmaceuticals PLC announced that Riad Mishlawi is stepping down as Chief Executive Officer and from the Board of Directors by mutual agreement.23

Said Darwazah, Hikma’s Executive Chairman and former CEO, will assume all CEO responsibilities with immediate effect.23

Khalid Nabilsi, currently Chief Financial Officer, will join Hikma’s Board of Directors and take on additional management responsibilities to support delivery of the Group’s strategic plans.23

The Board will launch a search for a new CEO in due course, while expressing confidence in the company’s growth prospects under Said Darwazah’s leadership.23

Hikma confirmed that its 2025 group guidance remains unchanged, and it plans to report full-year 2025 results on 26 February 2026.23

Hikma stated there is no additional information required to be disclosed regarding Khalid Nabilsi’s appointment under UK Listing Rule 6.4.8R, and details of Riad Mishlawi’s departure arrangements will be published in line with section 430(2B) of the UK Companies Act 2006.23

Sources:

2. https://www.hikma.com/news/hikma-announces-ceo-change-and-board-appointment/

3. https://www.hikma.com/media/f3fjuomy/hikma-ceo-change-and-board-appointment-final.pdf